If you have ever been told you are too old for hormone therapy, that you have been taking it too long, or that your symptoms don’t fit neatly into a treatment recommendation, you know how frustrating the menopause conversation can be.
I recently spent part of my weekend working through the American College of Obstetricians and Gynecologists’ menopause treatment guidelines. ACOG looks at hormone therapy, nonhormonal medications, and approaches such as movement, mindfulness, and acupuncture for managing symptoms.
There are things I am glad to see affirmed. There are things I have questions about. And there are places where my clinical experience adds something that a guideline cannot fully capture.
My biggest takeaway? We still need to have a thoughtful conversation about the individual woman seeking care.
Some welcome room for individual decisions
One of the things I was happiest to see was the approach to how long a woman can use menopause hormone therapy.
When I started prescribing in 2006, the guidance I worked with allowed for ten years of treatment. Then the conversation shifted toward five years. Women understandably began wondering when they would have to stop, sometimes well before they were ready to consider that question.
In these guidelines, I was pleased to see the emphasis move away from a predetermined time limit and toward reassessment and shared decision-making.
That means asking: Are the potential benefits still outweighing the risks for this particular woman?
I think that is the conversation we should have been having all along.
How are you feeling? What has treatment helped? Has your health history changed? What matters to you now?
Those questions make more sense to me than assuming a treatment stops being appropriate because a certain number of years has passed. Continuing treatment deserves thought. So does stopping it.
A guideline should inform the conversation
The guidelines describe a preferred window for starting hormone therapy: before age 60 and within ten years of the last menstrual period.
That information matters. But in my opinion, being outside that window should prompt an engaged conversation about your circumstances, rather than an automatic dismissal.
I am not suggesting everyone should take hormones. I am saying that age and time since your last period are part of a larger assessment.
What symptoms are you experiencing? What is your medical history? What are the potential risks? What benefit are you hoping for?
A guideline brings research into those decisions. The practitioner and patient still have work to do together.
This is where I keep coming back to the difference between population research and the person sitting in front of me. Research helps us understand patterns across groups of people. It cannot tell us with certainty how every individual will respond.
We are biochemically different. There is no way to know in advance exactly what will happen when we introduce a hormone into someone’s bloodstream.
That uncertainty is a reason to pay attention, have honest conversations, and reassess.
Mood deserves a more nuanced conversation
One point that stood out to me was ACOG’s recommendation against using menopause hormone therapy to treat depression.
Here is what I can say from practice: I often see mood improve with menopause hormone therapy.
Those two statements need room to exist in the same conversation.
Observing an improvement in mood does not establish hormone therapy as a treatment for depression. It does mean I want to hear about a woman’s mood when we discuss her experience of perimenopause and menopause.
Sleep, night sweats, and how you feel emotionally are all part of your daily life. You experience them together, even when treatment recommendations address them separately.
If your mood changes during this transition, that deserves attention. If it improves during treatment, that deserves attention, too.
Clinical experience has a place here. So does being clear about what that experience can and cannot tell us.
The details of treatment matter
I was glad to see attention paid to differences in how hormones are delivered and which formulations are used, including transdermal estrogen and the potential sleep benefits of oral progesterone.
“Hormone therapy” is a broad term. The details matter when we talk about both benefits and risks.
Some of the alternatives raised questions for me.
For example, the guidelines discuss conjugated estrogen combined with bazedoxifene, which offers an alternative to using a progestogen for uterine lining protection. Avoiding bleeding or breast tenderness may be an important consideration for some women. I understand that.
At the same time, I think there is a meaningful distinction to discuss between hormones with the same molecular structure as those our bodies make and medications that work differently. I want women to understand what they are being offered and why.
That distinction alone does not answer which option is appropriate. It belongs in the conversation.
I also raised an eyebrow at the discussion of using a Mirena IUD for uterine lining protection alongside estrogen, an off-label use described in the guidelines.
After reading through so many recommendations about what to do and what not to do, that flexibility caught my attention. It is a useful reminder that clinical decisions sometimes require judgment beyond a medication’s labeled use.
I appreciate seeing room for that judgment.
I have questions about the treatment toolbox
The guidelines also discuss nonhormonal medications and recognize approaches including cognitive behavioral therapy, mindfulness-based interventions, physical exercise, hypnosis, and acupuncture.
I am glad to see a range of tools included. Women need options, and women have different preferences about how they want to care for themselves.
The discussion of botanicals left me with more questions.
ACOG’s assessment, as I discussed in the videos, is that there is insufficient evidence to support the efficacy and safety of phytoestrogens and herbal supplements for these symptoms.
My experience attending conferences focused on botanical medicine is that practitioners are also drawing on studies when they make recommendations. I find myself wanting a fuller conversation about that research and how it is being interpreted.
I am not comfortable treating every botanical approach as interchangeable. Nor would I assume that something is safe or effective simply because it is plant based.
But I do want room to discuss the tools a woman is interested in, what we know about them, and what remains uncertain.
How do you want to take care of yourself? What approaches are you comfortable considering? Those questions belong alongside the research.
And yes, apparently we are calling it a “hot flush”
One detail made me smile: the preference for “hot flush” over “hot flash.”
The reasoning is that “flash” suggests something quicker than the experience many women describe. When that rise in heat lasts several minutes, I can appreciate the distinction.
What interested me more was the explanation of the brain’s temperature-regulating system and how declining estrogen may affect the signals involved.
That is the medicine of why. Understanding something about what is happening can help make an uncomfortable, sometimes bewildering experience more understandable.
Whether you call it a flash or a flush, the experience deserves to be taken seriously.
You are you
I welcome guidance that recognizes different treatment options, pays attention to formulation and delivery, and makes room for ongoing decisions between women and their practitioners.
I also think we need to be careful about asking any guideline to tell us everything about an individual woman.
Your symptoms, your health history, your preferences, and your response to treatment all matter. Research informs the conversation. Your experience gives us information we need to keep having it.
As I said in the videos: You are you. If you choose hormone therapy, you will have your own response.
That response is real. It deserves attention. And it belongs at the center of your care.
This article is for educational purposes. Decisions about menopause treatment should be made with your healthcare practitioner.
If you’d like to continue learning with me, I invite you to subscribe to my weekly newsletter, sent on Fridays. I share practical, evidence-informed guidance on women’s health, hormones, nourishment, and lifestyle practices that support long-term wellbeing.
When you sign up, as a thank-you, you’ll also receive my free guide on how to eat so you never have to diet again.
As with all of my articles, blogs, social media posts, etc, this article is educational and not a substitute for medical care. Please check with your clinician before changing your routine.

